Who is sponsoring NCT00358163?

NCT00358163 is sponsored by Dana-Farber Cancer Institute.

What drugs are being tested in NCT00358163?

Interventions in NCT00358163: PTK787/ZK 222584, paclitaxel.

What condition does NCT00358163 study?

NCT00358163 studies Metastatic Non-hematologic Malignancies.

Is NCT00358163 still recruiting?

NCT00358163 is currently terminated. Last updated 29 April 2022.

Last reviewed 2022-04-29 · How we verify

NCT00358163

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial of PTK787/ZK 222584 Plus Paclitaxel

Terminated Phase 1 Last updated 29 April 2022

What this trial tests

Phase 1 trial testing PTK787/ZK 222584 in Metastatic Non-hematologic Malignancies in 7 participants. Terminated before completion.

Timeline

26 April 2006

Primary endpoint
29 May 2008

29 May 2008

Quick facts

Lead sponsor	Dana-Farber Cancer Institute
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	7
Start date	26 April 2006
Primary completion	29 May 2008
Estimated completion	29 May 2008
Sites	3 locations across United States

Drugs / interventions tested

PTK787/ZK 222584
paclitaxel — full drug profile →

Conditions studied

Metastatic Non-hematologic Malignancies — all drugs for Metastatic Non-hematologic Malignancies →

Sponsor

Dana-Farber Cancer Institute

Who can join

18 and older, any sex, with Metastatic Non-hematologic Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PTK787/ZK 222584 is an inhibitor of VEGFR family tyrosine kinases. The primary objective of this study is to assess the safety of daily oral PTK787/ZK 222584 in combination with paclitaxel infused every 21 days. Secondary objectives include pharmacokinetic assessment of the impact of PTK787/ZK 222584 on paclitaxel metabolism and evaluation of tumor response to the investigational treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Dana-Farber Cancer Institute trials

Trials by the same sponsor.

NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00358163 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
Last refreshed: 29 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00358163.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing